In multiple sclerosis patients a single serum neurofilament light chain (sNFL) dosage is strongly associated with 12 months outcome: data from a real-life clinical setting
Malucchi, Simona, Bava, Cecilia Irene, Valentino, Paola, Martire, Serena, Lo Re, Marianna, Bertolotto, Antonio, Di Sapio, Alessia
Published in Journal of neurology (23.09.2024)
Published in Journal of neurology (23.09.2024)
Get full text
Journal Article
Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice
Valentino, Paola, Marnetto, Fabiana, Martire, Serena, Malucchi, Simona, Bava, Cecilia Irene, Popovic, Maja, Bertolotto, Antonio
Published in Multiple sclerosis and related disorders (01.09.2021)
Published in Multiple sclerosis and related disorders (01.09.2021)
Get full text
Journal Article
sNFL applicability as additional monitoring tool in natalizumab extended interval dosing regimen for RRMS patients
Valentino, Paola, Malucchi, Simona, Martire, Serena, Bava, Cecilia Irene, Capobianco, Marco Alfonso, Bertolotto, Antonio
Published in Multiple sclerosis and related disorders (01.11.2022)
Published in Multiple sclerosis and related disorders (01.11.2022)
Get full text
Journal Article
Prevalence of elevated sNFL in a real-world setting: Results on 908 patients with different multiple sclerosis types and treatment conditions
Bava, Cecilia Irene, Valentino, Paola, Malucchi, Simona, Bottero, Rugiada, Martire, Serena, Sapio, Alessia Di, Bertolotto, Antonio
Published in Multiple sclerosis and related disorders (01.08.2024)
Published in Multiple sclerosis and related disorders (01.08.2024)
Get full text
Journal Article